Transformation of substance use disorder treatment services during COVID-19 - A lasting change?

References

• Amram, O., Amiri, S., Thorn, E. L., Lutz, R., & Joudrey, P. J. (2021). Changes in methadone take-home dosing before and after COVID-19. Journal of Substance Abuse Treatment, 133(2022), 108552. https://doi.org/10.1016/j.jsat.2021.108552
   PubMedGoogle Scholar
• Aquino, E. M. L., Silveira, I. H., Pescarini, J. M., Aquino, R., de Souza-filho, J. A., Dos Rocha, A. S., Ferreira, A., Victor, A., Teixeira, C., Machado, D. B., Paixão, E., Alves, F. J. O., Pilecco, F., Menezes, G., Gabrielli, L., Leite, L., Almeida da de, M. C. C., Ortelan, N., Fernandes, Q. H. R. F., & Dos Lima, R. T. R. S. (2020). Social distancing measures to control the COVID-19 pandemic: Potential impacts and challenges in Brazil. Ciência & Saúde Coletiva, 25(suppl 1), 2423–2446. https://doi.org/10.1590/1413-81232020256.1.10502020
   PubMed Web of Science ®Google Scholar
• Arunogiri, S., & Lintzeris, N. (2021). Depot buprenorphine during COVID-19 in Australia: Opportunities and challenges. Journal of Substance Abuse Treatment, 124, 108221. https://doi.org/10.1016/j.jsat.2020.108221
   PubMed Web of Science ®Google Scholar
• Ashford, R. D., Brown, A. M., & Curtis, B. (2018). Systemic barriers in substance use disorder treatment: A prospective qualitative study of professionals in the field. Drug and Alcohol Dependence, 189(1), 62–69. https://doi.org/10.1016/j.drugalcdep.2018.04.033
   PubMedGoogle Scholar
• Bate, N. J., Xu, S. C., Pacilli, M., Roberts, L. J., Kimber, C., & Nataraja, R. M. (2021). Effect of the COVID-19 induced phase of massive telehealth uptake on end-user satisfaction. Internal Medicine Journal, 51(2), 206–214. https://doi.org/10.1111/imj.15222
   PubMed Web of Science ®Google Scholar
• Beardsley, K., Wish, E. D., Fitzelle, D. B., O’Grady, K., & Arria, A. M. (2003). Distance traveled to outpatient drug treatment and client retention. Journal of Substance Abuse Treatment, 25(4), 279–285. https://doi.org/10.1016/S0740-5472(03)00188-0
   PubMed Web of Science ®Google Scholar
• Bestsennyy, O., Gilbert, G., Harris, A., & Rost, J. (2021). Telehealth: A post-COVID-19 reality? McKinsey & Company. https://doi.org/10.1111/imj.15222https://www.mckinsey.com/industries/healthcare-systems-and-services/our-insights/telehealth-a-quarter-trillion-dollar-post-covid-19-reality
   Google Scholar
• Busch, A. B., Sugarman, D. E., Horvitz, L. E., & Greenfield, S. F. (2021). Telemedicine for treating mental health and substance use disorders: Reflections since the pandemic. Neuropsychopharmacology, 46(6), 1068–1070. https://doi.org/10.1038/s41386-021-00960-4
   PubMed Web of Science ®Google Scholar
• Calton, B., Abedini, N., & Fratkin, M. (2020). Telemedicine in the Time of Coronavirus. Journal of Pain and Symptom Management, 60(1), e12–e14. https://doi.org/10.1016/j.jpainsymman.2020.03.019
   PubMed Web of Science ®Google Scholar
• Cantor, J., McBain, R. K., Kofner, A., Hanson, R., Stein, B. D., & Yu, H. (2021). Telehealth adoption by mental health and substance use disorder treatment facilities in the COVID-19 pandemic. Psychiatric Services, 73(4), 411–417. https://doi.org/10.1176/appi.ps.202100191
   PubMed Web of Science ®Google Scholar
• Cantor, J., Stein, B. D., & Saloner, B. (2020). Telehealth capability among substance use disorder treatment facilities in counties with high versus low COVID-19 social distancing. Journal of Addiction Medicine, 14(6), e366–e368. https://doi.org/10.1097/ADM.0000000000000744
   PubMed Web of Science ®Google Scholar
• Cicero, T. J., Ellis, M. S., & Chilcoat, H. D. (2018). Understanding the use of diverted buprenorphine. Drug and Alcohol Dependence, 193, 117–123. https://doi.org/10.1016/j.drugalcdep.2018.09.007
   PubMed Web of Science ®Google Scholar
• Clark, S. A., Davis, C., Wightman, R. S., Wunsch, C., Keeler, L. A. J., Reddy, N., & Samuels, E. A. (2021). Using telehealth to improve buprenorphine access during and after COVID-19: A rapid response initiative in Rhode Island. Journal of Substance Abuse Treatment, 124, 108283. https://doi.org/10.1016/j.jsat.2021.108283
   PubMed Web of Science ®Google Scholar
• Columb, D., Hussain, R., & O’Gara, C. (2020). Addiction psychiatry and COVID-19: Impact on patients and service provision. Irish Journal of Psychological Medicine, 37(3), 164–168. https://doi.org/10.1017/ipm.2020.47
   PubMed Web of Science ®Google Scholar
• Contreras, C. M., Metzger, G. A., Beane, J. D., Dedhia, P. H., Ejaz, A., & Pawlik, T. M. (2020). Telemedicine: Patient-provider clinical engagement during the COVID-19 pandemic and beyond. Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract, 24(7), 1692–1697. https://doi.org/10.1007/s11605-020-04623-5
   PubMed Web of Science ®Google Scholar
• Courser, M. W., & Raffle, H. (2021). With crisis comes opportunity: Unanticipated benefits resulting from pivots to take-home naloxone (THN) programs during the COVID-19 pandemic. Journal of Substance Abuse Treatment, 122, 108220. https://doi.org/10.1016/j.jsat.2020.108220
   PubMed Web of Science ®Google Scholar
• Department for the Treatment of Substance Abuse, Mental Health Services, Israel Ministry of Health 21 July. (2021). [Work guidelines in the wake of the reduction in coronavirus morbidity]. https://doi.org/10.5281/zenodo.5642470.
   Google Scholar
• Department for the Treatment of Substance Abuse, Mental Health Services, Israel Ministry of Health, 12 July. (2020). [Readiness for the spread of the coronavirus—Update], https://doi.org/10.5281/zenodo.5642460
   Google Scholar
• Department of Health, Social Care, & Public Health England. (2021, April). COVID-19: Guidance for commissioners and providers of services for people who use drugs or alcohol. GOV.UK. https://www.gov.uk/government/publications/covid-19-guidance-for-commissioners-and-providers-of-services-for-people-who-use-drugs-or-alcohol/covid-19-guidance-for-commissioners-and-providers-of-services-for-people-who-use-drugs-or-alcohol
   Google Scholar
• European Monitoring Centre [EMCDDA] for Drugs and Drug Addiction. (2017). European facility survey questionnaire. EMCDDA Lisbon. https://www.emcdda.europa.eu/system/files/publications/4153/EFSQ-2017-Final.pdf
   Google Scholar
• Faur, R., Irazoqui, G., Pavlovsky, F., & Wikinski, S. (2021). Expanding accessibility: Outpatient intensive treatment for substance use disorder during covid-19 pandemic. Drug and Alcohol Dependence, 218, 108359. https://doi.org/10.1016/j.drugalcdep.2020.108359
   PubMed Web of Science ®Google Scholar
• Figgatt, M. C., Salazar, Z., Day, E., Vincent, L., & Dasgupta, N. (2021). Take-home dosing experiences among persons receiving methadone maintenance treatment during COVID-19. Journal of Substance Abuse Treatment, 123, 108276. https://doi.org/10.1016/j.jsat.2021.108276
   PubMed Web of Science ®Google Scholar
• Green, T. C., Bratberg, J., & Finnell, D. S. (2020). Opioid use disorder and the COVID 19 pandemic: A call to sustain regulatory easements and further expand access to treatment. Substance Abuse, 41(2), 147–149. https://doi.org/10.1080/08897077.2020.1752351
   PubMed Web of Science ®Google Scholar
• Grossman, Z., Chodick, G., Reingold, S. M., Chapnick, G., & Ashkenazi, S. 2020. The future of telemedicine visits after COVID-19: Perceptions of primary care pediatricians. Israel Journal of Health Policy Research, 9(1):53.
   PubMed Web of Science ®Google Scholar
• Hammersley, V., Donaghy, E., Parker, R., McNeilly, H., Atherton, H., Bikker, A., Campbell, J., & McKinstry, B. (2019). Comparing the content and quality of video, telephone, and face-to-face consultations: A non-randomized, quasi-experimental, exploratory study in UK primary care. British Journal of General Practice, 69(686), e595–e604. https://doi.org/10.3399/bjgp19X704573
   PubMed Web of Science ®Google Scholar
• Hatch-Maillette, M. A., Peavy, K. M., Tsui, J. I., Banta-Green, C. J., Woolworth, S., & Grekin, P. (2020). Re-thinking patient stability for methadone in opioid treatment programs during a global pandemic: Provider perspectives. Journal of Substance Abuse Treatment, 124, 108223. https://doi.org/10.1016/j.jsat.2020.108223
   Google Scholar
• Hser, Y.-I., Ober, A. J., Dopp, A. R., Lin, C., Osterhage, K. P., Clingan, S. E., Mooney, L. J., Curtis, M. E., Marsch, L. A., McLeman, B., Hichborn, E., Lester, L. S., Baldwin, L.-M., Liu, Y., Jacobs, P., & Saxon, A. J. (2021). Is telemedicine the answer to rural expansion of medication treatment for opioid use disorder? Early experiences in the feasibility study phase of a national drug abuse treatment clinical trials network trial. Addiction Science & Clinical Practice, 16(1), 24. https://doi.org/10.1186/s13722-021-00233-x
   PubMed Web of Science ®Google Scholar
• Israel Authority for Prevention of Violence, Alcohol and Drug Abuse. (2020). Informational for year 2020 of the drug and alcohol dependence treatment services. Accessed 10 October 2021. https://www.gov.il/BlobFolder/generalpage/treatment_rehabilitation_meidaon_2020/he/PDF_%D7%A9%D7%99%D7%A8%D7%95%D7%AA%D7%99%20%D7%94%D7%98%D7%99%D7%A4%D7%95%D7%9C%20%D7%91%D7%94%D7%AA%D7%9E%D7%9B%D7%A8%D7%95%D7%AA%20%D7%9C%D7%A1%D7%9E%D7%99%D7%9D%20%D7%95%D7%9C%D7%90%D7%9C%D7%9B%D7%95%D7%94%D7%95%D7%9C%20-%20%D7%9E%D7%99%D7%93%D7%A2%D7%95%D7%9F%202020.pdf
   Google Scholar
• Israel Ministry of Health. (2021). Coronavirus in Israel, general picture. Accessed 10 September 2021. https://datadashboard.health.gov.il/COVID-19/general
   Google Scholar
• Knopf, A. DEA, SAMHSA relax OTP/OBOT regulations due to COVID-19. Alcoholism & Drug Abuse Weekly. https://doi.org/10.1002/adaw.32664
   Google Scholar
• Leppla, I. E., & Gross, M. S. (2020). Optimizing medication treatment of opioid use disorder during COVID-19 (SARS-CoV-2). Journal of Addiction Medicine, 14(4), e1–e3. https://doi.org/10.1097/ADM.0000000000000678
   PubMed Web of Science ®Google Scholar
• Lev-Ran, S. (2020). When the Corona epidemic meets the addiction epidemic. Doctors Only. http://psychiatry.doctorsonly.co.il/2020/03/189148/
   Google Scholar
• Lopez, A. M., Lam, K., & Thota, R. (2021). Barriers and facilitators to telemedicine: Can you hear me now? American Society of Clinical Oncology Educational Book, 41, 25–36. https://doi.org/10.1200/EDBK_320827
   PubMedGoogle Scholar
• Madden, E. F., Christian, B. T., Lagisetty, P. A., Ray, B. R., & Sulzer, S. H. (2021). Treatment provider perceptions of take-home methadone regulation before and during COVID-19. Drug and Alcohol Dependence, 228 , 109100. https://doi.org/10.1016/j.drugalcdep.2021.109100
   PubMed Web of Science ®Google Scholar
• Mental Health Services. (2021, January). Guidelines for the mental health ambulatory services in COVID-19 routine. GOV.IL. https://www.gov.il/he/Departments/policies/mhd-468542121
   Google Scholar
• Molfenter, T., Roget, N., Chaple, M., Behlman, S., Cody, O., Hartzler, B., Johnson, E., Nichols, M., Stilen, P., & Becker, S. (2021). Use of telehealth in substance use disorder services during and after COVID-19: Online survey study. JMIR Mental Health, 8(2), e25835. https://doi.org/10.2196/25835
   PubMed Web of Science ®Google Scholar
• Pagano, A., Hosakote, S., Kapiteni, K., Straus, E. R., Wong, J., & Guydish, J. R. (2021). Impacts of COVID-19 on residential treatment programs for substance use disorder. Journal of Substance Abuse Treatment, 123, 108255. https://doi.org/10.1016/j.jsat.2020.108255
   PubMed Web of Science ®Google Scholar
• Patel, S. Y., Mehrotra, A., Huskamp, H. A., Uscher-Pines, L., Ganguli, I., & Barnett, M. L. (2021). Trends in outpatient care delivery and telemedicine during the COVID-19 pandemic in the US. JAMA Internal Medicine, 181(3), 388–391. https://doi.org/10.1001/jamainternmed.2020.5928
   PubMed Web of Science ®Google Scholar
• Piovani, D., Christodoulou, M. N., Hadjidemetriou, A., Pantavou, K., Zaza, P., Bagos, P. G., Bonovas, S., & Nikolopoulos, G. K. (2021). Effect of early application of social distancing interventions on COVID-19 mortality over the first pandemic wave: An analysis of longitudinal data from 37 countries. Journal of Infection, 82(1), 133–142. https://doi.org/10.1016/j.jinf.2020.11.033
   PubMed Web of Science ®Google Scholar
• Priester, M. A., Browne, T., Iachini, A., Clone, S., DeHart, D., & Seay, K. D. (2016). Treatment access barriers and disparities among individuals with co-occurring mental health and substance use disorders: An integrative literature review. Journal of Substance Abuse Treatment, 61, 47–59. https://doi.org/10.1016/j.jsat.2015.09.006
   PubMed Web of Science ®Google Scholar
• Pytell, J. D., & Rastegar, D. A. (2021). Down the drain: Reconsidering routine urine drug testing during the COVID-19 pandemic. Journal of Substance Abuse Treatment, 120, 108155. https://doi.org/10.1016/j.jsat.2020.108155
   PubMed Web of Science ®Google Scholar
• Rinott, E., Youngster, I., & Lewis, Y. E. (2021). Reduction in COVID-19 patients requiring mechanical ventilation following implementation of a national COVID-19 vaccination program—Israel, December 2020–February 2021. Morbidity and Mortality Weekly Report, 70(9), 326–328. https://doi.org/10.15585/mmwr.mm7009e3
   PubMed Web of Science ®Google Scholar
• Shachar, C., Engel, J., & Elwyn, G. (2020). Implications for telehealth in a postpandemic future: regulatory and privacy issues. JAMA, 323(23), 2375–2376. https://doi.org/10.1001/jama.2020.7943
   PubMed Web of Science ®Google Scholar
• Silverstein, S. M., Daniulaityte, R., Miller, S. C., Martins, S. S., & Carlson, R. G. (2020). On my own terms: Motivations for self-treating opioid-use disorder with non-prescribed buprenorphine. Drug and Alcohol Dependence, 210, 107958. https://doi.org/10.1016/j.drugalcdep.2020.107958
   PubMed Web of Science ®Google Scholar
• Stringer, K. L., Langdon, K. J., McKenzie, M., Brockmann, B., & Marotta, P. (2021). Leveraging COVID-19 to sustain regulatory flexibility in the treatment of opioid use disorder. Journal of Substance Abuse Treatment, 123, 108263. https://doi.org/10.1016/j.jsat.2020.108263
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration [SAMHSA]. Opioid Treatment Program (OTP) guidance. Accessed 12 October 2021. https://www.samhsa.gov/sites/default/files/otp-guidance-20200316.pdf
   Google Scholar
• Substance Abuse and Mental Health Services Administration [SAMHSA]. (2021, January 27). Become a Buprenorphine Waivered Practitioner. https://www.samhsa.gov/medication-assisted-treatment/become-buprenorphine-waivered-practitioner
   Google Scholar
• Thirthalli, J., Manjunatha, N., & Math, S. B. (2020). Unmask the mind! Importance of video consultations in psychiatry during COVID-19 pandemic. Schizophrenia Research, 222, 482–483. https://doi.org/10.1016/j.schres.2020.06.005
   PubMed Web of Science ®Google Scholar
• Thomas, E. E., Haydon, H. M., Mehrotra, A., Caffery, L. J., Snoswell, C. L., Banbury, A., & Smith, A. C. (2020). Building on the momentum: Sustaining telehealth beyond COVID-19. Journal of Telemedicine and Telecare, 1–8. https://doi.org/10.1177/1357633X20960638
   Google Scholar
• Thomas, S. J., Moreira, E. D., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Polack, F. P., Zerbini, C., Bailey, R., Swanson, K. A., Xu, X., Roychoudhury, S., Koury, K., Bouguermouh, S., Kalina, W. V., Cooper, D., Frenck, R. W., & Jansen, K. U. (2021). Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. New England Journal of Medicine, 385, 1761–1773. https://doi.org/10.1056/NEJMoa2110345.
   PubMed Web of Science ®Google Scholar
• Trujols, J., Larrabeiti, A., Sànchez, O., Madrid, M., De Andrés, S., & Duran-Sindreu, S. (2020). Increased flexibility in methadone take-home scheduling during the COVID-19 pandemic: should this practice be incorporated into routine clinical care? Journal of Substance Abuse Treatment, 119, 108154. https://doi.org/10.1016/j.jsat.2020.108154
   PubMed Web of Science ®Google Scholar
• Uscher-Pines, L., & Martineau, M. (2021). Telehealth after COVID-19: Clarifying policy goals for a way forward (perspective). RAND corporation. https://www.rand.org/pubs/perspectives/PEA1089-1.html
   Google Scholar
• Uscher-Pines, L., Sousa, J., Raja, P., Mehrotra, A., Barnett, M., & Huskamp, H. A. (2020). Treatment of opioid use disorder during COVID-19: Experiences of clinicians transitioning to telemedicine. Journal of Substance Abuse Treatment, 118, 108124. https://doi.org/10.1016/j.jsat.2020.108124
   PubMed Web of Science ®Google Scholar
• Walker, P. G. T., Whittaker, C., Watson, O. J., Baguelin, M., Winskill, P., Hamlet, A., Djafaara, B. A., Cucunubá, Z., Mesa, D. O., Green, W., Thompson, H., Nayagam, S., Ainslie, K. E. C., Bhatia, S., Bhatt, S., Boonyasiri, A., Boyd, O., Brazeau, N. F., Cattarino, L., … Ghani, A. C. (2020). The impact of COVID-19 and strategies for mitigation and suppression in low- and middle-income countries. Science, 369(6502), 413–422. https://doi.org/10.1126/science.abc0035
   PubMed Web of Science ®Google Scholar
• Wei, Y., & Shah, R. (2020). Substance use disorder in the COVID-19 pandemic: A systematic review of vulnerabilities and complications. Pharmaceuticals, 13(7), 155. https://doi.org/10.3390/ph13070155
   Web of Science ®Google Scholar
• Zachrison, K. S., Boggs, K. M., Hayden, E. M., Espinola, J. A., & Camargo, C. A. (2020). Understanding barriers to telemedicine implementation in rural emergency departments. Annals of Emergency Medicine, 75(3), 392–399. https://doi.org/10.1016/j.annemergmed.2019.06.026
   PubMed Web of Science ®Google Scholar